Literature DB >> 15834645

Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis.

G R Davies1, D R Altmann, A Hadjiprocopis, W Rashid, D T Chard, C M Griffin, P S Tofts, G J Barker, R Kapoor, A J Thompson, D H Miller.   

Abstract

Abnormalities within normal-appearing grey and white matter (NAGM and NAWM) occur early in the clinical course of multiple sclerosis (MS) and can be detected in-vivo using the magnetisation transfer ratio (MTR). To better characterize the rates of change in both tissues and to ascertain when such changes begin, we serially studied a cohort of minimally disabled, early relapsing-remitting MS patients, using NAGM and NAWM MTR histograms. Twenty-three patients with clinically definite early relapsing-remitting MS (mean disease duration at baseline 1.9 years), and 19 healthy controls were studied. A magnetisation transfer imaging sequence was acquired yearly for two years. Twenty-one patients and 10 controls completed followup. NAWM and NAGM MTR histograms were derived and mean MTR calculated. A hierarchical regression analysis, adjusting for brain parenchymal fraction,was used to assess MTR change over time. MS NAWM and NAGM MTR were significantly reduced in comparison with controls at baseline and, in patients, both measures decreased further during follow-up: (-0.10 pu/year, p=0.001 and -0.18 pu/year, p<0.001 respectively). The rate of MTR decrease was significantly greater in NAGM than NAWM (p=0.004). Under the assumption that such changes are linear, backward extrapolation of the observed rates of change suggested that NAWM abnormality began before symptom onset. We conclude that increasing MTR abnormalities in NAWM and NAGM are observed early in the course of relapsing-remitting MS. It is now important to investigate whether these measures are predictive of future disability, and consequently, whether MTR could be used as a surrogate marker in therapeutic trials.

Entities:  

Mesh:

Year:  2005        PMID: 15834645     DOI: 10.1007/s00415-005-0808-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

2.  Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability.

Authors:  Nicola De Stefano; Sridar Narayanan; Simon J Francis; Steve Smith; Marzia Mortilla; M Carmela Tartaglia; Maria L Bartolozzi; Leonello Guidi; Antonio Federico; Douglas L Arnold
Journal:  Arch Neurol       Date:  2002-10

3.  Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

Authors:  Marco Rovaris; Federica Agosta; Maria Pia Sormani; Matilde Inglese; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  Brain       Date:  2003-08-22       Impact factor: 13.501

4.  Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.

Authors:  A Traboulsee; J Dehmeshki; Kevin R Peters; C M Griffin; P A Brex; N Silver; O Ciccarrelli; D T Chard; G J Barker; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

5.  Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging.

Authors:  V Dousset; R I Grossman; K N Ramer; M D Schnall; L H Young; F Gonzalez-Scarano; E Lavi; J A Cohen
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

6.  Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis.

Authors:  Cornelia Laule; Irene M Vavasour; Kenneth P Whittall; Joel Oger; Donald W Paty; David K B Li; Alex L MacKay; Douglas L Arnold
Journal:  J Neurol       Date:  2003-08       Impact factor: 4.849

7.  Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

Authors:  P D Molyneux; G J Barker; F Barkhof; K Beckmann; F Dahlke; M Filippi; M Ghazi; D Hahn; D MacManus; C Polman; C Pozzilli; L Kappos; A J Thompson; K Wagner; T Yousry; D H Miller
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

Review 8.  Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.

Authors:  M Filippi; V Dousset; H F McFarland; D H Miller; R I Grossman
Journal:  J Magn Reson Imaging       Date:  2002-05       Impact factor: 4.813

9.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; G J M Parker; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

10.  The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.

Authors:  Declan T Chard; Geoffrey J M Parker; Colette M B Griffin; Alan J Thompson; David H Miller
Journal:  J Magn Reson Imaging       Date:  2002-03       Impact factor: 4.813

View more
  24 in total

Review 1.  Multicentre imaging measurements for oncology and in the brain.

Authors:  P S Tofts; D J Collins
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  Texture analysis: a review of neurologic MR imaging applications.

Authors:  A Kassner; R E Thornhill
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-15       Impact factor: 3.825

3.  MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis.

Authors:  P Tortorella; M A Rocca; D M Mezzapesa; A Ghezzi; L Lamantia; G Comi; M Filippi
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

4.  Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging.

Authors:  Waqar Rashid; Andreas Hadjiprocopis; Gerard Davies; Collette Griffin; Declan Chard; Michaela Tiberio; Dan Altmann; Claudia Wheeler-Kingshott; Dan Tozer; Alan Thompson; David H Miller
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

5.  Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.

Authors:  Michael Amann; Athina Papadopoulou; Michaela Andelova; Stefano Magon; Nicole Mueller-Lenke; Yvonne Naegelin; Christoph Stippich; Ernst Wilhelm Radue; Oliver Bieri; Ludwig Kappos; Till Sprenger
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

6.  A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration.

Authors:  Kader K Oguz; Asli Kurne; Aysegul Oz Aksu; Aslihan Taskiran; Erdem Karabulut; Rana Karabudak
Journal:  J Neurol       Date:  2010-03-11       Impact factor: 4.849

7.  Comprehensive brain analysis with automated high-resolution magnetization transfer measurements.

Authors:  Ying Wu; Hongyan Du; Pippa Storey; Christopher Glielmi; Fiona Malone; Shawn Sidharthan; Ann Ragin; Paul S Tofts; Robert R Edelman
Journal:  J Magn Reson Imaging       Date:  2011-10-11       Impact factor: 4.813

8.  Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; R A C Hughes; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

Review 9.  Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve.

Authors:  Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

10.  Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

Authors:  L K Fisniku; D R Altmann; M Cercignani; D J Tozer; D T Chard; J S Jackson; K A Miszkiel; K Schmierer; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2009-05-12       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.